These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12431027)

  • 1. Palonosetron (Helsinn).
    Stacher G
    Curr Opin Investig Drugs; 2002 Oct; 3(10):1502-7. PubMed ID: 12431027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
    Navari RM
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1577-86. PubMed ID: 19929251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann C; Herrstedt J
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):137-48. PubMed ID: 20131990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
    Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
    J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting.
    Saito M; Tsukuda M
    Expert Opin Pharmacother; 2010 Apr; 11(6):1003-14. PubMed ID: 20307224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palonosetron (Aloxi) for prevention of nausea and vomiting due to cancer chemotherapy.
    Med Lett Drugs Ther; 2004 Mar; 46(1179):27-8. PubMed ID: 15057189
    [No Abstract]   [Full Text] [Related]  

  • 9. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
    Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
    Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palonosetron to prevent nausea and vomiting in children undergoing BMT: efficacy and safety.
    Ripaldi M; Parasole R; De Simone G; D'Amico MR; Migliorati R; Zanotta G; Loffredo G; Petruzziello F; Poggi V
    Bone Marrow Transplant; 2010 Nov; 45(11):1663-4. PubMed ID: 20173793
    [No Abstract]   [Full Text] [Related]  

  • 11. Palonosetron. RS 25259, RS 25259 197.
    Drugs R D; 1999 Oct; 2(4):251-2. PubMed ID: 10659403
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
    Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
    J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting serotonin antagonist (Palonosetron) and the NK-1 receptor antagonists: does extended duration of action improve efficacy?
    Melton MS; Nielsen KC; Tucker M; Klein SM; Gan TJ
    Anesthesiol Clin; 2014 Jun; 32(2):505-16. PubMed ID: 24882134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children.
    Sepúlveda-Vildósola AC; Betanzos-Cabrera Y; Lastiri GG; Rivera-Márquez H; Villasis-Keever MA; Del Angel VW; Díaz FC; López-Aguilar E
    Arch Med Res; 2008 Aug; 39(6):601-6. PubMed ID: 18662592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical role of palonosetron for patients receiving cisplatin-based chemotherapy].
    Labianca R; Mandalà M; Clerici M
    Tumori; 2008; 94(2):suppl 23-5. PubMed ID: 18564622
    [No Abstract]   [Full Text] [Related]  

  • 17. [Palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in Italy: pharmacologic, clinical and economic aspects].
    Pradelli L; Eandi M
    Tumori; 2008; 94(2):suppl 26-32. PubMed ID: 18564623
    [No Abstract]   [Full Text] [Related]  

  • 18. Neurokinin-1 and novel serotonin antagonists for postoperative and postdischarge nausea and vomiting.
    George E; Hornuss C; Apfel CC
    Curr Opin Anaesthesiol; 2010 Dec; 23(6):714-21. PubMed ID: 20871394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor.
    Rojas C; Stathis M; Thomas AG; Massuda EB; Alt J; Zhang J; Rubenstein E; Sebastiani S; Cantoreggi S; Snyder SH; Slusher B
    Anesth Analg; 2008 Aug; 107(2):469-78. PubMed ID: 18633025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Meta-analysis of phase III studies with palonosetron in the prevention of vomiting induced by moderately emetogenic chemotherapy].
    Di Maio M; Gallo C; Perrone F
    Tumori; 2008; 94(2):suppl 14-22. PubMed ID: 18564621
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.